Pfizer’s cost cuts that began last year have stretched to the closure of a well-known internal R&D team that focused on partnering with physician-scientists to launch new medicines, including one that ultimately became the center of a $7.1 billion acquisition from Roche.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,